Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in…
<!-- Name:DistributionId Value:1000802689 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Metastatic Breast Cancer
Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM…
<!-- Name:DistributionId Value:1000802689 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022…
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically…
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical…
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene,…
Effect of Diabetes Control on Breast Cancer Outcomes
To date, there has been little research conducted on the effects of diabetes, and in particular, the impact of poor blood sugar control on advanced breast cancer outcomes. Existing studies…
Metastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook |…
New York, USAMetastatic Breast Cancer Pipeline Report: Emerging Therapies and Treatment Outlook | De, May 24, 2022 (GLOBE NEWSWIRE) -- Metastatic Breast Cancer Pipeline Report: Emerging…
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast…
COLUMBUS, Ohio, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat…